Biocon and Voluntis deal to transform insulin biosimilars personalised care through digital therapeutics: GlobalData Read more
‘Lupin has gained significant momentum towards development of biosimilar products with primary focus on regulated markets’ Read more
FDA puts in efforts to help make development of biosimilar and interchangeable insulin products Read more